Department of Biomedical Engineering, Bone Tissue Engineering Center, Carnegie Mellon University, Pittsburgh, PA 15213, USA.
J Tissue Eng Regen Med. 2012 May;6(5):404-13. doi: 10.1002/term.442. Epub 2011 Jul 11.
Poly(ε-caprolactone fumarate) (PCLF) scaffold formulations were assessed as a delivery system for recombinant human bone morphogenetic protein (rhBMP-2) for bone tissue engineering. The formulations included PCLF with combinations of poly(vinyl alcohol) (PVA) and hydroxyapatite (HA). The assessments included in vitro and in vivo assays. In vitro assays validated cell attachment using a pre-osteoblast cell line (MC3T3-E1). Additionally, in vitro release profiles of rhBMP-2 from PCLF scaffolds were determined up to 21 days. The data suggested that PCLF incorporated with PVA and HA accelerated rhBMP-2 release and that the released protein was bioactive. For the in vivo study, a critical-sized defect (CSD) model in rabbit calvaria was used to test PCLF scaffolds. At 6 weeks post-implantation, significantly more bone formation was measured in PCLF scaffolds containing rhBMP-2 than in scaffolds without rhBMP-2. In conclusion, we demonstrated that PCLF delivered biologically active rhBMP-2, promoted bone healing in a CSD and has potential as a bone tissue engineering scaffold.
聚（ε-己内酯富马酸酯）（PCLF）支架配方被评估为用于骨组织工程的重组人骨形态发生蛋白（rhBMP-2）的递送系统。这些配方包括 PCLF 与聚乙烯醇（PVA）和羟基磷灰石（HA）的组合。评估包括体外和体内试验。体外试验使用成骨前体细胞系（MC3T3-E1）验证细胞附着。此外，还确定了 rhBMP-2 从 PCLF 支架中的体外释放曲线，最长可达 21 天。数据表明，掺入 PVA 和 HA 的 PCLF 加速了 rhBMP-2 的释放，并且释放的蛋白质具有生物活性。对于体内研究，使用兔颅骨的临界尺寸缺陷（CSD）模型来测试 PCLF 支架。在植入后 6 周时，在含有 rhBMP-2 的 PCLF 支架中测量到的骨形成明显多于不含 rhBMP-2 的支架。总之，我们证明 PCLF 递送具有生物活性的 rhBMP-2，促进了 CSD 中的骨愈合，并且具有作为骨组织工程支架的潜力。
